Analysis of Adverse Drug Reactions with Carbamazepine and Oxcarbazepine at a Tertiary Care Hospital
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To describe adverse drug reactions (ADRs) to carbamazepine (CBZ) and oxcarbazepine (OXC), including severe cutaneous ADRs, at a tertiary care hospital over a 10-year period. Materials and Methods: The frequency and clinical features of ADRs caused by CBZ and OXC were analyzed using the pharmacovigilance database and spontaneous ADR reporting data of Yonsei University Severance Hospital & Dental Hospital (Seoul, Korea) from January 1, 2010 to January 31, 2020. Results: Among 10419 cases prescribed CBZ and OXC, 204 ADR cases were reported. The incidences of ADRs were 1.8% and 2.2% for CBZ and OXC respectively, with no significant difference (p=0.169). The most common clinical presentations were skin disorders. Female patients had relatively more frequent ADRs than male patients. Although mild skin ADRs were more frequent with OXC, nervous system disorders, general disorders, and hepatobiliary disorders occurred more often with CBZ. There were six reports of severe cutaneous adverse reactions to CBZ, while OXC had none. Both CBZ and OXC caused ADRs at daily doses lower than the recommended initial dose. Conclusion: Due to lower incidence of severe ADRs with OXC than CBZ, we suggest OXC as a first-line prescription.
Abstract
Purpose: To describe adverse drug reactions (ADRs) to carbamazepine (CBZ) and oxcarbazepine (OXC), including severe cutaneous ADRs, at a tertiary care hospital over a 10-year period. Materials and Methods: The frequency and clinical features of ADRs caused by CBZ and OXC were analyzed using the pharmacovigilance database and spontaneous ADR reporting data of Yonsei University Severance Hospital & Dental Hospital (Seoul, Korea) from January 1, 2010 to January 31, 2020. Results: Among 10419 cases prescribed CBZ and OXC, 204 ADR cases were reported. The incidences of ADRs were 1.8% and 2.2% for CBZ and OXC respectively, with no significant difference (p=0.169). The most common clinical presentations were skin disorders. Female patients had relatively more frequent ADRs than male patients. Although mild skin ADRs were more frequent with OXC, nervous system disorders, general disorders, and hepatobiliary disorders occurred more often with CBZ. There were six reports of severe cutaneous adverse reactions to CBZ, while OXC had none. Both CBZ and OXC caused ADRs at daily doses lower than the recommended initial dose. Conclusion: Due to lower incidence of severe ADRs with OXC than CBZ, we suggest OXC as a first-line prescription.
참고문헌 (22)
- Blom S, "Trigeminal neuralgia : its treatment with a new anticonvulsant drug(G-32883)", Lancet, 1, pp.839~840 (1962)
- Hirschfeld RMA, "American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: compendium 2002", pp.547~634 (2002), American Psychiatric Association
- Ghaemi SN, "Oxcarbazepine treatment of bipolar disorder", J Clin Psychiatry, 64, pp.943~945 (2003)
- Lertratanangkoon K, "Metabolism of carbamazepine", Drug Metab Dispos, 10, pp.1~10 (1982)
- Gayford JJ, "The side-effects of carbamazepine", Proc R Soc Med, 62, pp.615~616 (1969)
- Hyun Kyung Kim, "Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008–2017", Journal of Korean Medical Science, 35(4), pp.1~9 (2020), 대한의학회[DOI]
- Breton H, "Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma", J Chromatogr B Analyt Technol Biomed Life Sci, 828, pp.80~90 (2005)
- Houtkooper MA, "Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?", Epilepsia, 28, pp.693~698 (1987)
- Dam M, "A doubleblind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy", Epilepsy Res, 3, pp.70~76 (1989)
- Yang CY, "Severe cutaneous adverse reactions to antiepileptic drugs in Asians", Neurology, 77, pp.2025~2033 (2011)
- 강민규, "Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea", Yonsei Medical Journal, 60(2), pp.208~215 (2019), 연세대학교의과대학[DOI]
- Korinthenberg R, "The metabolization of carbamazepine to CBZ-10, 11-epoxide in children from the newborn age to adolescence", Neuropediatrics, 25, pp.214~216 (1994)
- Yu YM, "Patterns of adverse drug reactions in different age groups : analysis of spontaneous reports by community pharmacists", PLoS One, 10, pp.e0132916~ (2015)
- Domecq C, "Sex-related variations in the frequency and characteristics of adverse drug reactions", Int J Clin Pharmacol Ther Toxicol, 18, pp.362~366 (1980)
- Rademaker M, "Do women have more adverse drug reactions", Am J Clin Dermatol, 2, pp.349~351 (2001)
- Montastruc JL, "Gender differences in adverse drug reactions : analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France", Fundam Clin Pharmacol, 16, pp.343~346 (2002)
- Schmidt D, "What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs", Epilepsy Behav, 5, pp.627~635 (2004)
- Roujeau JC, "Treatment of severe drug eruptions", J Dermatol, 26, pp.718~722 (1999)
- McDevitt JT, "Accuracy of tablet splitting", Pharmacotherapy, 18, pp.193~197 (1998)
- Verrue C, "Tabletsplitting : a common yet not so innocent practice", J Adv Nurs, 67, pp.26~32 (2011)
- Quinzler R, "The frequency of inappropriate tablet splitting in primary care", Eur J Clin Pharmacol, 62, pp.1065~1073 (2006)
- Thiessard F, "Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system(1986-2001)", Drug Saf, 28, pp.731~740 (2005)